Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698243 · ClinicalTrials.gov registry record · Phase 1
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT00698243: Completed Phase 1 study, sponsored by Astellas Pharma.
NCT00698243 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 128 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00698243, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in patients with advanced solid tumors or lymphoma, namely, intermittent, weekly, and continuous.
Interventions
- DRUG OSI-027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT00698243 record still lists
NCT00698243 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher).
The record links to 0 conditions, and to 1 intervention - of which OSI-027 is the first listed.
NCT00698243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00698243 about?
NCT00698243 is a clinical study titled "Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma". The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in patients with advanced solid tumors or lymphoma, namely, intermittent,...
What is the current status of trial NCT00698243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2008-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00698243?
The interventions under investigation include: OSI-027 (DRUG).
Who is sponsoring clinical trial NCT00698243?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00698243's enrollment target sits among peer trials
128 452nd of 2000 higher than 1,542 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia